Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Jetstream G3™ Calcium Study

This study has been completed.
Information provided by (Responsible Party):
Boston Scientific Corporation Identifier:
First received: December 20, 2010
Last updated: October 19, 2015
Last verified: October 2015
To investigate the treatment effects with the Jetstream G3 System in moderate to severely calcified peripheral artery disease in the common femoral, superficial femoral or popliteal arteries using intravascular ultrasound (IVUS).

Condition Intervention Phase
Peripheral Arterial Disease
Device: Jetstream Atherectomy System
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Single-Arm Study to Evaluate the Effects of the Jetstream G3 System on Calcified Peripheral Vascular Lesions

Resource links provided by NLM:

Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Luminal Area Change [ Time Frame: Day 0 ]
    lumen area change as measured by intravascular ultrasound (IVUS)

Secondary Outcome Measures:
  • Adjunctive Therapy Use [ Time Frame: Day 0 ]
  • Residual Diameter Stenosis [ Time Frame: Day 0 ]
    lumen diameter stenosis change post-atherectomy

Enrollment: 55
Study Start Date: January 2011
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Patients with PAD
Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium
Device: Jetstream Atherectomy System
to perform atherectomy on calcified lesions


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The patient is ≥ 18 years of age.
  2. Patient has claudication determined to be due to femoropopliteal lesion(s) requiring revascularization.
  3. The target lesion(s) is/are located in the common femoral, superficial femoral or popliteal arteries.
  4. The reference vessel lumen (proximal to target lesion) is ≥ 3.0mm.
  5. The patient is an acceptable candidate for percutaneous intervention using the Jetstream G3 System in accordance with its labeled indications and instructions for use.
  6. The patient has signed approved informed consent.
  7. Moderate or severe vessel obstructive intraluminal calcification as demonstrated by IVUS and angiography.

Exclusion Criteria:

  1. Patient has an uncontrollable allergy to nitinol, stainless steel or other stent materials or to contrast agent.
  2. Patient is unable to take appropriate anti-platelet therapy.
  3. Patient has no distal runoff vessels.
  4. Deep wall calcium.
  5. Interventional treatment is intended for in-stent restenosis at the peripheral vascular site.
  6. Patient has target vessel with moderate or severe angulation (e.g., >30 degrees) or tortuosity at the treatment segment.
  7. Patient has a history of coagulopathy or hypercoagulable bleeding disorder.
  8. Patient is receiving hemodialysis or has impaired renal function (creatinine is > 2.5 mg/dl) at the time of treatment.
  9. Patient has evidence of intracranial or gastrointestinal bleeding within the past 3 months.
  10. Patient has had severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days.
  11. Patient is pregnant or nursing a child.
  12. Intended interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than the Jetstream G3 System.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01273623

United States, Arizona
Arizona Heart Institute
Phoenix, Arizona, United States, 85006
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, Michigan
St. John Hopital
Detroit, Michigan, United States, 48236
United States, Tennessee
Mercy Medical Center
Knoxville, Tennessee, United States, 37934
United States, Wisconsin
Wheaton Franciscan Healthcare
Milwaukee, Wisconsin, United States, 53210
Sponsors and Collaborators
Boston Scientific Corporation
Principal Investigator: Tom Davis, MD St. John Hospital
Principal Investigator: Malcolm Foster Mercy Medical Center
Principal Investigator: Venkatesh Ramaiah, MD Arizona Heart Institute
Principal Investigator: Joseph Ricotta, MD Emory University
Principal Investigator: Thomas Shimshak, MD Wheaton Franciscan Healthcare
  More Information

Responsible Party: Boston Scientific Corporation Identifier: NCT01273623     History of Changes
Other Study ID Numbers: D1139
Study First Received: December 20, 2010
Results First Received: April 16, 2015
Last Updated: October 19, 2015

Keywords provided by Boston Scientific Corporation:
PAD, Peripheral Arterial Disease, Calcium, Atherectomy, Jetstream

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on April 24, 2017